# A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

> **NCT01766336** · PHASE2 · TERMINATED · sponsor: **OPKO Health, Inc.** · enrollment: 296 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Group 1 ELND005
- **DRUG:** Group 2 ELND005

## Key facts

- **NCT ID:** NCT01766336
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766336, "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01766336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*